How to conquer the largest pharmaceutical market in the world? – Keynote by Prof. Matthias P. Schönermark at the „Orphan Drugs and Rare Diseases“ Congress

The major stakeholders of the orphan drug industry will come together in California this summer at the “Orphan Drugs and Rare Diseases 2018 Americas West coast“ congress . This event, hosted by Paradigm Global Events, will provide a unique platform for all the participants to network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organizations, orphan drugs developers as well as regional and local manufacturers and to discuss critical issues influencing the future of orphan drugs (drugs for rare diseases).

This year, the congress will take place on the 25th and 26th June at the Westin Hotel in San Diego  and we are happy to announce that SKC is attending.

Prof. Matthias P. Schönermark, M.D., Ph. D., managing director of SKC, will hold a keynote speech at the congress on day one about “Orphan Drugs in Europe – Conquering the largest pharmaceutical market”. Come to the congress to learn more about the barriers of market access in Europe. Prof. Schönermark will address significant questions such as: which specific conditions does a pharmaceutical entrepreneur have to expect in the different countries? And which features need to be considered due to the orphan drug status? What can be learned from best and worst cases?

Join Prof. Matthias P. Schönermark, M.D., Ph.D. to gain profound insights into the European market, the largest pharmaceutical market in the world!

Furthermore, you have the chance to interact with Prof. Schönermark at the panel discussion “Advancing Orphan Drugs Innovation and Access” in the afternoon on day two. As the panelist of the 40-minute discussion, Prof. Schönermark will discuss relevant topics such as the key drivers that will steer the innovation and access of orphan drug and the existing regulations and policies utilized by countries to enable access to orphan drugs. Beyond that, the critical differences between countries in terms of legislations, regulations and policies implemented will also be outlined during the panel-discussion.

SKC is looking forward to seeing you at the congress. We are the leading and most reputable strategy consultancy in the German health care sector. Especially orphan drugs with their specific German market access process have been a field of work for us in recent years. Gain more insights with our whitepaper Orphan Drugs in German – lessons learned from AMNOG.

BY Prof. Matthias P. Schönermark, M.D., Ph.D., managing director and Karolin Priese, MBA

Please find more information here:
Orphan Drugs and Rare Diseases 2018 Americas West Coast – program
Orphan Drugs and Rare Diseases 2018 Americas – West Coast